



## Clinical trial results:

### A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome Event

#### Summary

EudraCT number	2009-012852-26
Trial protocol	ES DE PT GB LT EE DK LV IT NL SE FR FI BG BE NO AT
Global end of trial date	11 February 2015

#### Results information

Result version number	v1 (current)
This version publication date	29 July 2016
First version publication date	29 July 2016

#### Trial information

##### Trial identification

Sponsor protocol code	EFC11319
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01147250
WHO universal trial number (UTN)	U1111-1116-5558
Other trial identifiers	Study Name: ELIXA

Notes:

##### Sponsors

Sponsor organisation name	Sanofi aventis recherche & développement
Sponsor organisation address	1 avenue Pierre Brossolette, Chilly-Mazarin, France, 91380
Public contact	Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com
Scientific contact	Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 March 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	11 February 2015
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality [composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina] compared to placebo in type 2 diabetic subjects who recently experienced a spontaneous, biomarker-positive acute coronary syndrome (ACS) event.

Protection of trial subjects:

Subjects were fully informed of all pertinent aspects of the clinical trial via informed consent form (ICF) with investigator as well as the possibility to discontinue at any time in language and terms appropriate for the subject and considering the local culture. During the course of the trial, subjects were provided with individual subject cards indicating the nature of the trial the subject is participating, contact details and any information needed in the event of a medical emergency. Collected personal data and human biological samples were processed in compliance with the Sanofi-Aventis Group Personal Data Protection Charter ensuring that the Group abides by the laws governing personal data protection in force in all countries in which it operates.

Background therapy:

Antidiabetic medications were permitted (except other glucagon like peptide-1 [GLP1] receptor agonist or dipeptidyl peptidase-IV [DPP-IV] inhibitors) . Adjustment was allowed in order to manage glycemic control in accordance with clinical practice guidelines.

Evidence for comparator: -

Actual start date of recruitment	24 June 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 27
Country: Number of subjects enrolled	Norway: 30
Country: Number of subjects enrolled	Poland: 250
Country: Number of subjects enrolled	Portugal: 24
Country: Number of subjects enrolled	Romania: 230
Country: Number of subjects enrolled	Spain: 154
Country: Number of subjects enrolled	Sweden: 43
Country: Number of subjects enrolled	United Kingdom: 125
Country: Number of subjects enrolled	Austria: 4
Country: Number of subjects enrolled	Belgium: 15
Country: Number of subjects enrolled	Bulgaria: 76
Country: Number of subjects enrolled	Denmark: 54

Country: Number of subjects enrolled	Estonia: 52
Country: Number of subjects enrolled	Finland: 44
Country: Number of subjects enrolled	France: 38
Country: Number of subjects enrolled	Germany: 96
Country: Number of subjects enrolled	Italy: 69
Country: Number of subjects enrolled	Latvia: 56
Country: Number of subjects enrolled	Lithuania: 48
Country: Number of subjects enrolled	Argentina: 399
Country: Number of subjects enrolled	Australia: 17
Country: Number of subjects enrolled	Belarus: 34
Country: Number of subjects enrolled	Brazil: 448
Country: Number of subjects enrolled	Canada: 111
Country: Number of subjects enrolled	Chile: 246
Country: Number of subjects enrolled	China: 113
Country: Number of subjects enrolled	Colombia: 265
Country: Number of subjects enrolled	Ecuador: 27
Country: Number of subjects enrolled	Egypt: 6
Country: Number of subjects enrolled	Georgia: 58
Country: Number of subjects enrolled	Guatemala: 142
Country: Number of subjects enrolled	India: 317
Country: Number of subjects enrolled	Israel: 65
Country: Number of subjects enrolled	Japan: 103
Country: Number of subjects enrolled	Korea, Republic of: 74
Country: Number of subjects enrolled	Mexico: 301
Country: Number of subjects enrolled	Panama: 9
Country: Number of subjects enrolled	Peru: 107
Country: Number of subjects enrolled	Philippines: 50
Country: Number of subjects enrolled	Russian Federation: 587
Country: Number of subjects enrolled	Serbia: 69
Country: Number of subjects enrolled	South Africa: 130
Country: Number of subjects enrolled	Switzerland: 8
Country: Number of subjects enrolled	Taiwan: 29
Country: Number of subjects enrolled	Tunisia: 26
Country: Number of subjects enrolled	Turkey: 55
Country: Number of subjects enrolled	Ukraine: 127
Country: Number of subjects enrolled	United Arab Emirates: 14
Country: Number of subjects enrolled	United States: 696
Worldwide total number of subjects	6068
EEA total number of subjects	1435

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	4025
From 65 to 84 years	2023
85 years and over	20

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted at 828 centers in 49 countries between June 24, 2010 and July 24, 2013. A total of 7719 subjects were screened, 1651 of whom were screen failures. Screen failures were mainly due to exclusion criteria met.

### Pre-assignment

Screening details:

7627 subjects underwent 1 week placebo run-in period. 1559 were run-in failures due to exclusion criteria met. A total of 6068 subjects were randomized 1:1 to lixisenatide and placebo arms in double-blind treatment period. Duration of study was event driven until approximately 844 positively adjudicated primary CV outcome events.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo

Arm description:

Placebo matched to lixisenatide once daily (QD) up to end of treatment (median exposure 23 months).

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled pen
Routes of administration	Subcutaneous use

Dosage and administration details:

Volume-matched placebo was self-administered QD within 1 hour before breakfast in the morning.

<b>Arm title</b>	Lixisenatide
------------------	--------------

Arm description:

Lixisenatide 10 mcg QD for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to end of treatment (median exposure 22 months).

Arm type	Experimental
Investigational medicinal product name	Lixisenatide
Investigational medicinal product code	AVE0010
Other name	
Pharmaceutical forms	Solution for injection in pre-filled pen
Routes of administration	Subcutaneous use

Dosage and administration details:

Lixisenatide was self-administered QD within 1 hour before breakfast in the morning. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg.

<b>Number of subjects in period 1</b>	Placebo	Lixisenatide
Started	3034	3034
Treated	3032	3031
Completed	2924	2929
Not completed	110	105
Consent withdrawn by subject	83	88
Site termination by sponsor	13	5
Other than specified	-	1
Lost to follow-up	14	11

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
Reporting group description:	
Placebo matched to lixisenatide once daily (QD) up to end of treatment (median exposure 23 months).	
Reporting group title	Lixisenatide
Reporting group description:	
Lixisenatide 10 mcg QD for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to end of treatment (median exposure 22 months).	

Reporting group values	Placebo	Lixisenatide	Total
Number of subjects	3034	3034	6068
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	60.6	59.9	
standard deviation	± 9.6	± 9.7	-
Gender categorical			
Units: Subjects			
Female	938	923	1861
Male	2096	2111	4207
Race			
Units: Subjects			
Caucasian/White	2318	2258	4576
Black	103	118	221
Asian/Oriental	367	404	771
Other	246	254	500
Ethnicity			
Units: Subjects			
Hispanic	903	865	1768
Not Hispanic	2131	2169	4300
Qualifying ACS event			
Units: Subjects			
ST-segment elevation MI	1317	1349	2666
Non ST-segment elevation MI	1183	1165	2348
Unstable angina	528	514	1042
Unclassified	4	5	9
Not qualifying ACS event	2	1	3
Body Mass Index (BMI)			
N=3032, 3033			
Units: kg/m <sup>2</sup>			
arithmetic mean	30.2	30.12	
standard deviation	± 5.79	± 5.6	-
Body Weight			
N=3032, 3033			
Units: kg			

arithmetic mean	85.06	84.64	
standard deviation	± 19.64	± 19.21	-
Glycosylated Hemoglobin (HbA1c)			
N=3033, 3034			
Units: Percentage of HbA1c			
arithmetic mean	7.64	7.72	
standard deviation	± 1.28	± 1.32	-
Duration of Diabetes			
N=3034, 3031			
Units: Years			
arithmetic mean	9.38	9.2	
standard deviation	± 8.32	± 8.19	-



## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description: Placebo matched to lixisenatide once daily (QD) up to end of treatment (median exposure 23 months).	
Reporting group title	Lixisenatide
Reporting group description: Lixisenatide 10 mcg QD for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to end of treatment (median exposure 22 months).	

### Primary: Time to First Occurrence of Primary CV Event: CV Death, Non-fatal MI, Non-fatal Stroke or Hospitalization for Unstable Angina

End point title	Time to First Occurrence of Primary CV Event: CV Death, Non-fatal MI, Non-fatal Stroke or Hospitalization for Unstable Angina
End point description: Kaplan Meier plots of the cumulative incidence rate by treatment groups were used to depict the onset of primary CV endpoint over time. Number of observed subjects with endpoint events were reported. A CV event adjudication committee (CAC) reviewed and adjudicated, in a blinded fashion, all potential events. Analysis was done on intent-to-treat (ITT) population defined as all randomized subjects analyzed according to the treatment group allocated at randomization.	
End point type	Primary
End point timeframe: From randomization up to the end of study (median follow-up of 25 months)	

End point values	Placebo	Lixisenatide		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3034	3034		
Units: subjects				
number (not applicable)	399	406		

### Statistical analyses

Statistical analysis title	Lixisenatide vs Placebo
Statistical analysis description: Analysis was performed using Cox proportional hazards model with treatment groups, and region (North America, South and Central America, Western Europe, Eastern Europe, Africa/Near East, and Asia/Pacific) as covariates, and the associated two-sided 95% confidence interval (CI).	
Comparison groups	Lixisenatide v Placebo

Number of subjects included in analysis	6068
Analysis specification	Pre-specified
Analysis type	non-inferiority
Method	Cox proportional hazard model
Parameter estimate	Hazard ratio (HR)
Point estimate	1.017
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.886
upper limit	1.168

<b>Statistical analysis title</b>	Lixisenatide vs Placebo
-----------------------------------	-------------------------

Statistical analysis description:

Analysis was performed using Cox proportional hazards model with treatment groups, and region (North America, South and Central America, Western Europe, Eastern Europe, Africa/Near East, and Asia/Pacific) as covariates, and the associated two-sided 95% CI.

Comparison groups	Lixisenatide v Placebo
Number of subjects included in analysis	6068
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8542 <sup>[1]</sup>
Method	Cox proportional hazard model
Parameter estimate	Hazard ratio (HR)
Point estimate	1.017
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.886
upper limit	1.168

Notes:

[1] - P-value was calculated using log-rank test.

### **Secondary: Time to First Occurrence of CV Event: CV Death, Non-fatal MI, Non-fatal Stroke, Hospitalization for Unstable Angina or Hospitalization For Heart Failure**

End point title	Time to First Occurrence of CV Event: CV Death, Non-fatal MI, Non-fatal Stroke, Hospitalization for Unstable Angina or Hospitalization For Heart Failure
-----------------	--

End point description:

All CV events were positively adjudicated by the CAC, used in the analysis of the composite CV endpoint comprised of CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failure. Number of observed subjects with endpoint events were reported. Analysis was done on ITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization up to the end of study (median follow-up of 25 months)

End point values	Placebo	Lixisenatide		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3034	3034		
Units: subjects				
number (not applicable)	469	456		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Time to First Occurrence of CV Event: CV Death, Non-fatal MI, Non-fatal Stroke, Hospitalization for Unstable Angina, Hospitalization For Heart Failure or Coronary Revascularization Procedure

End point title	Time to First Occurrence of CV Event: CV Death, Non-fatal MI, Non-fatal Stroke, Hospitalization for Unstable Angina, Hospitalization For Heart Failure or Coronary Revascularization Procedure
-----------------	--

End point description:

All CV events were positively adjudicated by CAC, used in the analysis of the composite CV endpoint comprised of CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, hospitalization for heart failure, or coronary revascularization procedure. Number of observed subjects with endpoint events were reported. Analysis was done on ITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization up to the end of study (median follow-up of 25 months)

End point values	Placebo	Lixisenatide		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3034	3034		
Units: subjects				
number (not applicable)	659	661		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change From Baseline in The Urinary Albumin/Creatinine Ratio (UACR) at Week 108

End point title	Percent Change From Baseline in The Urinary Albumin/Creatinine Ratio (UACR) at Week 108
-----------------	---

End point description:

Presence of albumin in urine is a marker of nephropathy, an important microvascular complication of diabetes. UACR was defined as the ratio: mg of albumin per gram of creatinine. UACR data were log transformed before the analysis. Calculation was based on geometric mean. Analysis was performed on ITT population. Missing data was imputed using last observation carried forward (LOCF) using the last available post-baseline UACR before Week 108 as the value at Week 108, regardless of treatment discontinuation or not.

End point type	Secondary
End point timeframe:	
Baseline to Week 108 (LOCF)	

End point values	Placebo	Lixisenatide		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2830	2803		
Units: Percent change				
geometric mean (standard error)	34.21 (± 3.09)	24.17 (± 2.84)		

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All Adverse Events (AEs) were collected from signature of the informed consent form up to study end regardless of seriousness or relationship to IMP. Cardiovascular efficacy endpoint events were collected and analyzed separately within same time frame.

Adverse event reporting additional description:

Reported AEs and deaths are treatment emergent that is AEs that developed/worsened and deaths that occurred during 'on treatment period' (time from first administration of IMP up to 3 days after last administration of IMP). All cause deaths include cardiovascular deaths (primary efficacy endpoint) and non cardiovascular deaths resulting from AEs.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.1
--------------------	------

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects exposed to Placebo matched to lixisenatide QD. (Median exposure: 23 months)

Reporting group title	Lixisenatide
-----------------------	--------------

Reporting group description:

Subjects exposed to Lixisenatide 10 mcg QD for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to 225 weeks. (Median exposure: 22 months)

Serious adverse events	Placebo	Lixisenatide	
Total subjects affected by serious adverse events			
subjects affected / exposed	669 / 3032 (22.06%)	625 / 3031 (20.62%)	
number of deaths (all causes)	96	93	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma Gastric			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Adenocarcinoma Of Colon			
subjects affected / exposed	2 / 3032 (0.07%)	6 / 3031 (0.20%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 2	
Adenocarcinoma Pancreas			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Adenosquamous Cell Lung Cancer			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-Cell Lymphoma			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-Cell Unclassifiable Lymphoma Low Grade			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal Cell Carcinoma			
subjects affected / exposed	5 / 3032 (0.16%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 7	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign Neoplasm			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign Renal Neoplasm			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign Salivary Gland Neoplasm			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign Small Intestinal Neoplasm			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder Cancer			
subjects affected / exposed	4 / 3032 (0.13%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder Neoplasm			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain Neoplasm			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Breast Cancer			
subjects affected / exposed	1 / 3032 (0.03%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast Neoplasm			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial Carcinoma			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Chronic Lymphocytic Leukaemia			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clear Cell Renal Cell Carcinoma			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon Adenoma			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon Cancer			
subjects affected / exposed	3 / 3032 (0.10%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 3	1 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Colon Cancer Metastatic			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon Cancer Recurrent			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon Neoplasm			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal Adenocarcinoma			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diffuse Large B-Cell Lymphoma			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Endometrial Cancer			



subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibromatosis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder Cancer			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastric Cancer			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastric Cancer Stage Iv			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Glioblastoma Multiforme			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatocellular Carcinoma			
subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Iris Melanoma			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Keratoacanthoma			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lip Squamous Cell Carcinoma			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipoma			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung Adenocarcinoma			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lung Cancer Metastatic			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung Neoplasm Malignant			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoma			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant Melanoma			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant Pleural Effusion			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases To Central Nervous System			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases To Liver			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases To Lung			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases To Pancreas			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic Pain			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-Small Cell Lung Cancer			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-Hodgkin's Lymphoma			

subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ovarian Cancer			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ovarian Cancer Stage Iii			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ovarian Epithelial Cancer			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic Carcinoma			
subjects affected / exposed	3 / 3032 (0.10%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	1 / 2	0 / 0	
Pancreatic Carcinoma Metastatic			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Papillary Thyroid Cancer			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phaeochromocytoma			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal Cancer			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pituitary Tumour Benign			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma Cell Myeloma			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate Cancer			
subjects affected / exposed	7 / 3032 (0.23%)	10 / 3031 (0.33%)	
occurrences causally related to treatment / all	0 / 7	0 / 10	
deaths causally related to treatment / all	0 / 1	0 / 0	
Prostate Cancer Metastatic			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate Cancer Stage I			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic Adenoma			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal Adenocarcinoma			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal Adenoma			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal Cancer			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal Cancer			
subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal Cancer Metastatic			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal Cell Carcinoma			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal Neoplasm			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Salivary Gland Neoplasm			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin Cancer			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small Cell Lung Cancer			

subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Small Cell Lung Cancer Metastatic			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Small Intestine Adenocarcinoma			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous Cell Carcinoma			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous Cell Carcinoma Of Lung			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous Cell Carcinoma Of Skin			
subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Testicular Neoplasm			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional Cell Carcinoma			
subjects affected / exposed	3 / 3032 (0.10%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Accelerated Hypertension			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic Dissection			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic Stenosis			
subjects affected / exposed	2 / 3032 (0.07%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic Thrombosis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial Disorder			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial Occlusive Disease			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteritis			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood Pressure Inadequately Controlled			



subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circulatory Collapse			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep Vein Thrombosis			
subjects affected / exposed	2 / 3032 (0.07%)	5 / 3031 (0.16%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic Vascular Disorder			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Essential Hypertension			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extremity Necrosis			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral Artery Aneurysm			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Granulomatosis With Polyangiitis			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	9 / 3032 (0.30%)	5 / 3031 (0.16%)	
occurrences causally related to treatment / all	0 / 10	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive Crisis			
subjects affected / exposed	13 / 3032 (0.43%)	15 / 3031 (0.49%)	
occurrences causally related to treatment / all	0 / 15	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive Emergency			
subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	6 / 3032 (0.20%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 6	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemic Shock			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intermittent Claudication			
subjects affected / exposed	4 / 3032 (0.13%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leriche Syndrome			

subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic Hypotension			
subjects affected / exposed	4 / 3032 (0.13%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral Arterial Occlusive Disease			
subjects affected / exposed	7 / 3032 (0.23%)	5 / 3031 (0.16%)	
occurrences causally related to treatment / all	0 / 11	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral Artery Aneurysm			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral Artery Stenosis			
subjects affected / exposed	2 / 3032 (0.07%)	5 / 3031 (0.16%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral Artery Thrombosis			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral Embolism			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral Ischaemia			
subjects affected / exposed	3 / 3032 (0.10%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral Vascular Disorder			

subjects affected / exposed	4 / 3032 (0.13%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral Venous Disease			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock Haemorrhagic			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular Occlusion			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular Stenosis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasculitis Necrotising			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous Thrombosis Limb			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Cardioplegia			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystectomy			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Debridement			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip Arthroplasty			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implantable Defibrillator Insertion			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraocular Lens Implant			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee Arthroplasty			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leg Amputation			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral Artery Bypass			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleurodesis			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toe Amputation			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Arterial Restenosis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthenia			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest Discomfort			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest Pain			
subjects affected / exposed	0 / 3032 (0.00%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 2	
Coronary Artery Restenosis			
subjects affected / exposed	2 / 3032 (0.07%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	2 / 3032 (0.07%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 2	0 / 3	
Gait Disturbance			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired Healing			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant Site Extravasation			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inflammation			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Local Swelling			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			
subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multi-Organ Failure			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Non-Cardiac Chest Pain			
subjects affected / exposed	42 / 3032 (1.39%)	46 / 3031 (1.52%)	
occurrences causally related to treatment / all	0 / 48	0 / 52	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema Peripheral			

subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyp			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden Death			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Systemic Inflammatory Response Syndrome			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis In Device			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vessel Puncture Site Haematoma			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic Reaction			



subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic Shock			
subjects affected / exposed	0 / 3032 (0.00%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug Hypersensitivity			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Social circumstances			
Joint Prosthesis User			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Adenomyosis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign Prostatic Hyperplasia			
subjects affected / exposed	2 / 3032 (0.07%)	5 / 3031 (0.16%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metrorrhagia			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian Cyst			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Ovarian Cyst Ruptured			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatism			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatitis			
subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatomegaly			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine Prolapse			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval Ulceration			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute Pulmonary Oedema			
subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Acute Respiratory Distress Syndrome			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	

Acute Respiratory Failure			
subjects affected / exposed	5 / 3032 (0.16%)	6 / 3031 (0.20%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 0	
Asthma			
subjects affected / exposed	4 / 3032 (0.13%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthmatic Crisis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis Chronic			
subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchospasm			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic Obstructive Pulmonary Disease			
subjects affected / exposed	14 / 3032 (0.46%)	15 / 3031 (0.49%)	
occurrences causally related to treatment / all	0 / 16	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cough			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	3 / 3032 (0.10%)	7 / 3031 (0.23%)	
occurrences causally related to treatment / all	0 / 5	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 0	
Dyspnoea Exertional			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemothorax			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrothorax			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial Lung Disease			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Laryngeal Stenosis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung Disorder			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung Infiltration			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal Polyps			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive Airways Disorder			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal Mass			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pickwickian Syndrome			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural Effusion			
subjects affected / exposed	4 / 3032 (0.13%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleurisy			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia Aspiration			

subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary Embolism			
subjects affected / exposed	8 / 3032 (0.26%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 8	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary Hypertension			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary Mass			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary Toxicity			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory Acidosis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory Disorder			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory Distress			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory Failure			

subjects affected / exposed	2 / 3032 (0.07%)	4 / 3031 (0.13%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory Tract Haemorrhage			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sleep Apnoea Syndrome			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vocal Cord Disorder			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wheezing			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Adjustment Disorder			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol Abuse			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Completed Suicide			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Confusional State			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Conversion Disorder			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	3 / 3032 (0.10%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mania			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychogenic Seizure			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicidal Ideation			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Alanine Aminotransferase Increased			
subjects affected / exposed	7 / 3032 (0.23%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiogram			



subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood Creatinine Increased			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood Glucose Abnormal			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood Glucose Fluctuation			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood Glucose Increased			
subjects affected / exposed	4 / 3032 (0.13%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood Pressure Increased			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood Sodium Decreased			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carbohydrate Antigen 19-9 Increased			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac Pacemaker Evaluation			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Catheterisation Cardiac			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crystal Urine Present			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram Abnormal			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glycosylated Haemoglobin Increased			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic Specific Antigen Increased			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urine Output Decreased			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight Decreased			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Accidental Overdose			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acetabulum Fracture			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol Poisoning			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Allergic Transfusion Reaction			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle Fracture			
subjects affected / exposed	3 / 3032 (0.10%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthropod Sting			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain Contusion			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cartilage Injury			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest Injury			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral Injury			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	7 / 3032 (0.23%)	7 / 3031 (0.23%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Femoral Neck Fracture			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur Fracture			
subjects affected / exposed	3 / 3032 (0.10%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibula Fracture			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot Fracture			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Forearm Fracture			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign Body			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gun Shot Wound			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hand Fracture			
subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head Injury			
subjects affected / exposed	2 / 3032 (0.07%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip Fracture			
subjects affected / exposed	8 / 3032 (0.26%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 8	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus Fracture			
subjects affected / exposed	3 / 3032 (0.10%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision Site Haematoma			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional Hernia			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint Dislocation			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint Injury			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament Rupture			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament Sprain			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb Injury			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower Limb Fracture			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar Vertebral Fracture			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medication Error			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus Injury			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple Injuries			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post Procedural Complication			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post Procedural Discharge			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post Procedural Haematoma			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post Procedural Haemorrhage			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative Fever			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative Thoracic Procedure Complication			
subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural Pain			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pubis Fracture			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius Fracture			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib Fracture			
subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scar			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal Haematoma			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull Fracture			



subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft Tissue Injury			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal Fracture			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sports Injury			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Subdural Haematoma			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural Haemorrhage			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia Fracture			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity To Various Agents			
subjects affected / exposed	2 / 3032 (0.07%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulna Fracture			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular Pseudoaneurysm			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound Haemorrhage			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Angina Pectoris			
subjects affected / exposed	23 / 3032 (0.76%)	23 / 3031 (0.76%)	
occurrences causally related to treatment / all	0 / 24	0 / 27	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis Coronary Artery			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial Fibrillation			
subjects affected / exposed	30 / 3032 (0.99%)	23 / 3031 (0.76%)	
occurrences causally related to treatment / all	0 / 37	0 / 28	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial Flutter			
subjects affected / exposed	5 / 3032 (0.16%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial Tachycardia			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular Block			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular Block Complete			
subjects affected / exposed	8 / 3032 (0.26%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 8	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular Block First Degree			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular Block Second Degree			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bifascicular Block			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	5 / 3032 (0.16%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac Arrest			
subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardio-Respiratory Arrest			

subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary Artery Disease			
subjects affected / exposed	5 / 3032 (0.16%)	4 / 3031 (0.13%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary Artery Occlusion			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive Heart Disease			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracardiac Thrombus			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic Cardiomyopathy			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left Ventricular Dysfunction			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral Valve Incompetence			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial Ischaemia			

subjects affected / exposed	3 / 3032 (0.10%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocarditis			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palpitations			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial Effusion			
subjects affected / exposed	3 / 3032 (0.10%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial Haemorrhage			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sick Sinus Syndrome			
subjects affected / exposed	5 / 3032 (0.16%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular Tachycardia			
subjects affected / exposed	4 / 3032 (0.13%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachyarrhythmia			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Trifascicular Block			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular Extrasystoles			
subjects affected / exposed	3 / 3032 (0.10%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular Tachycardia			
subjects affected / exposed	8 / 3032 (0.26%)	9 / 3031 (0.30%)	
occurrences causally related to treatment / all	0 / 13	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Amyotrophic Lateral Sclerosis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aphasia			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain Injury			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid Artery Dissection			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid Artery Occlusion			
subjects affected / exposed	3 / 3032 (0.10%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid Artery Stenosis			
subjects affected / exposed	6 / 3032 (0.20%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carpal Tunnel Syndrome			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral Haemorrhage			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral Ischaemia			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical Radiculopathy			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cognitive Disorder			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Convulsion			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depressed Level Of Consciousness			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic Neuropathy			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Essential Tremor			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial Nerve Disorder			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial Paresis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			



subjects affected / exposed	0 / 3032 (0.00%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoaesthesia			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic Unconsciousness			
subjects affected / exposed	3 / 3032 (0.10%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	1 / 3	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxic-Ischaemic Encephalopathy			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial Haematoma			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss Of Consciousness			
subjects affected / exposed	4 / 3032 (0.13%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar Radiculopathy			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine			

subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Morton's Neuralgia			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple Sclerosis Relapse			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathy Peripheral			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Optic Neuritis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraplegia			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral Sensorimotor Neuropathy			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	0 / 3032 (0.00%)	4 / 3031 (0.13%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychomotor Hyperactivity			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyramidal Tract Syndrome			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radial Nerve Palsy			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radicular Pain			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiculitis Lumbosacral			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sciatica			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	16 / 3032 (0.53%)	16 / 3031 (0.53%)	
occurrences causally related to treatment / all	1 / 17	0 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient Ischaemic Attack			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Trigeminal Neuralgia			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viith Nerve Paralysis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vith Nerve Paralysis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	9 / 3032 (0.30%)	8 / 3031 (0.26%)	
occurrences causally related to treatment / all	1 / 9	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coagulopathy			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic Anaemia			
subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Increased Tendency To Bruise			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron Deficiency Anaemia			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrogenic Anaemia			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normochromic Normocytic Anaemia			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pernicious Anaemia			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Deafness Neurosensory			
subjects affected / exposed	0 / 3032 (0.00%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden Hearing Loss			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo Labyrinthine			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo Positional			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Amaurosis Fugax			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angle Closure Glaucoma			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerotic Retinopathy			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blindness Unilateral			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract			
subjects affected / exposed	5 / 3032 (0.16%)	4 / 3031 (0.13%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract Nuclear			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic Eye Disease			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic Retinal Oedema			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucoma			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Open Angle Glaucoma			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ophthalmoplegia			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal Detachment			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uveitis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous Haemorrhage			
subjects affected / exposed	3 / 3032 (0.10%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal Adhesions			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal Distension			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal Hernia			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal Incarcerated Hernia			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal Pain			
subjects affected / exposed	7 / 3032 (0.23%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	3 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal Pain Upper			
subjects affected / exposed	2 / 3032 (0.07%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal Rigidity			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal Wall Haemorrhage			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal Fistula			



subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic Gastritis			
subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crohn's Disease			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic Gastroparesis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	4 / 3032 (0.13%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	1 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticular Perforation			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal Ulcer			
subjects affected / exposed	3 / 3032 (0.10%)	4 / 3031 (0.13%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal Ulcer Haemorrhage			
subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenitis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspepsia			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epigastric Discomfort			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Faecal Vomiting			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Food Poisoning			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric Disorder			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric Polyps			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric Ulcer			
subjects affected / exposed	2 / 3032 (0.07%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric Ulcer Haemorrhage			
subjects affected / exposed	2 / 3032 (0.07%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	4 / 3032 (0.13%)	7 / 3031 (0.23%)	
occurrences causally related to treatment / all	1 / 4	3 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis Erosive			
subjects affected / exposed	3 / 3032 (0.10%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis Haemorrhagic			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroduodenitis			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroduodenitis Haemorrhagic			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal Disorder			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal Haemorrhage			
subjects affected / exposed	6 / 3032 (0.20%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	1 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal Reflux Disease			
subjects affected / exposed	1 / 3032 (0.03%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gingival Bleeding			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoidal Haemorrhage			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired Gastric Emptying			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal Hernia			
subjects affected / exposed	3 / 3032 (0.10%)	5 / 3031 (0.16%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal Haemorrhage			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal Ischaemia			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Intestinal Obstruction			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large Intestine Perforation			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large Intestine Polyp			

subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower Gastrointestinal Haemorrhage			
subjects affected / exposed	3 / 3032 (0.10%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mallory-Weiss Syndrome			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			
subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	3 / 3032 (0.10%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstruction Gastric			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal Ulcer			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			

subjects affected / exposed	3 / 3032 (0.10%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	1 / 3	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis Acute			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis Chronic			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritoneal Haemorrhage			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal Haemorrhage			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small Intestinal Ulcer Haemorrhage			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical Hernia			
subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical Hernia, Obstructive			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper Gastrointestinal Haemorrhage			

subjects affected / exposed	4 / 3032 (0.13%)	4 / 3031 (0.13%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Vomiting			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Bile Duct Stone			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			
subjects affected / exposed	5 / 3032 (0.16%)	9 / 3031 (0.30%)	
occurrences causally related to treatment / all	0 / 5	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis Acute			
subjects affected / exposed	7 / 3032 (0.23%)	10 / 3031 (0.33%)	
occurrences causally related to treatment / all	1 / 7	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis Chronic			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	6 / 3032 (0.20%)	13 / 3031 (0.43%)	
occurrences causally related to treatment / all	0 / 6	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestasis			



subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug-Induced Liver Injury			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder Polyp			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic Cirrhosis			
subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic Function Abnormal			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis Acute			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic Hepatitis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver Injury			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Diabetic Foot			

subjects affected / exposed	4 / 3032 (0.13%)	8 / 3031 (0.26%)	
occurrences causally related to treatment / all	0 / 5	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperhidrosis			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pruritus Generalised			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriasis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin Ulcer			
subjects affected / exposed	10 / 3032 (0.33%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 10	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Swelling Face			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urticaria			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Calculus Bladder			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus Ureteric			
subjects affected / exposed	3 / 3032 (0.10%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus Urinary			
subjects affected / exposed	2 / 3032 (0.07%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	2 / 3032 (0.07%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	8 / 3032 (0.26%)	7 / 3031 (0.23%)	
occurrences causally related to treatment / all	0 / 8	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy Toxic			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal Artery Stenosis			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal Colic			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal Failure			
subjects affected / exposed	5 / 3032 (0.16%)	6 / 3031 (0.20%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal Failure Acute			
subjects affected / exposed	20 / 3032 (0.66%)	20 / 3031 (0.66%)	
occurrences causally related to treatment / all	0 / 21	0 / 20	
deaths causally related to treatment / all	0 / 1	0 / 0	
Renal Failure Chronic			
subjects affected / exposed	4 / 3032 (0.13%)	6 / 3031 (0.20%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 0	
Renal Impairment			
subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral Meatus Stenosis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary Bladder Haemorrhage			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary Retention			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Goitre			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperparathyroidism			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperthyroidism			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	3 / 3032 (0.10%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back Pain			
subjects affected / exposed	4 / 3032 (0.13%)	4 / 3031 (0.13%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone Pain			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Coccydynia			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dupuytren's Contracture			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fasciitis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot Deformity			
subjects affected / exposed	3 / 3032 (0.10%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture Malunion			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemarthrosis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral Disc Protrusion			
subjects affected / exposed	3 / 3032 (0.10%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint Instability			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar Spinal Stenosis			

subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal Chest Pain			
subjects affected / exposed	3 / 3032 (0.10%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal Discomfort			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal Pain			
subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myalgia			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteitis			
subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	7 / 3032 (0.23%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 8	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain In Extremity			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain In Jaw			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periarthritis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid Arthritis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator Cuff Syndrome			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal Column Stenosis			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal Osteoarthritis			
subjects affected / exposed	0 / 3032 (0.00%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systemic Lupus Erythematosus			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Trigger Finger			



subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
<b>Abdominal Abscess</b>			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Abdominal Sepsis</b>			
subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Abdominal Wall Infection</b>			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Abscess Limb</b>			
subjects affected / exposed	3 / 3032 (0.10%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Amoebic Dysentery</b>			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Anal Abscess</b>			
subjects affected / exposed	2 / 3032 (0.07%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Appendicitis</b>			
subjects affected / exposed	3 / 3032 (0.10%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 3	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Appendicitis Perforated</b>			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis Infective			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial Pyelonephritis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone Abscess			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	2 / 3032 (0.07%)	5 / 3031 (0.16%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis Bacterial			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis Viral			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopneumonia			

subjects affected / exposed	2 / 3032 (0.07%)	6 / 3031 (0.20%)	
occurrences causally related to treatment / all	0 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Burn Infection			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carbuncle			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cat Scratch Disease			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	18 / 3032 (0.59%)	17 / 3031 (0.56%)	
occurrences causally related to treatment / all	0 / 20	1 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic Hepatitis B			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic Hepatitis C			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic Sinusitis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium Difficile Colitis			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colonic Abscess			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dengue Fever			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device Related Infection			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic Foot Infection			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea Infectious			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	1 / 3032 (0.03%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Empyema			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	7 / 3032 (0.23%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 10	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder Abscess			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			
subjects affected / exposed	7 / 3032 (0.23%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis Viral			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	9 / 3032 (0.30%)	13 / 3031 (0.43%)	
occurrences causally related to treatment / all	0 / 10	1 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis Clostridial			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis Viral			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal Infection			

subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin Abscess			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
H1n1 Influenza			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma Infection			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Helicobacter Gastritis			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected Bites			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected Skin Ulcer			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective Exacerbation Of Chronic Obstructive Airways Disease			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			

subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Klebsiella Sepsis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver Abscess			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lobar Pneumonia			
subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised Infection			
subjects affected / exposed	4 / 3032 (0.13%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower Respiratory Tract Infection			
subjects affected / exposed	3 / 3032 (0.10%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lung Infection			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mediastinitis			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis			

subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mycobacterial Infection			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nail Bed Infection			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasopharyngitis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	9 / 3032 (0.30%)	4 / 3031 (0.13%)	
occurrences causally related to treatment / all	0 / 9	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis Acute			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis Chronic			
subjects affected / exposed	2 / 3032 (0.07%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis Fungal			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis Media Chronic			



subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraspinal Abscess			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paronychia			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	2 / 3032 (0.07%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pilonidal Cyst			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleurisy Viral			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	51 / 3032 (1.68%)	36 / 3031 (1.19%)	
occurrences causally related to treatment / all	0 / 59	0 / 36	
deaths causally related to treatment / all	0 / 2	0 / 1	
Pneumonia Bacterial			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post Procedural Infection			

subjects affected / exposed	1 / 3032 (0.03%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative Wound Infection			
subjects affected / exposed	5 / 3032 (0.16%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoas Abscess			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary Sepsis			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pulmonary Tuberculosis			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Puncture Site Abscess			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	4 / 3032 (0.13%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis Acute			
subjects affected / exposed	4 / 3032 (0.13%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis Chronic			

subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal Abscess			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory Tract Infection			
subjects affected / exposed	4 / 3032 (0.13%)	6 / 3031 (0.20%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal Abscess			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	10 / 3032 (0.33%)	8 / 3031 (0.26%)	
occurrences causally related to treatment / all	0 / 11	1 / 8	
deaths causally related to treatment / all	0 / 3	1 / 4	
Septic Shock			
subjects affected / exposed	3 / 3032 (0.10%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 1	
Soft Tissue Infection			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal Infection			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal Osteomyelitis			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous Abscess			
subjects affected / exposed	3 / 3032 (0.10%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdiaphragmatic Abscess			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tick-Borne Fever			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth Abscess			
subjects affected / exposed	0 / 3032 (0.00%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxoplasmosis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper Respiratory Tract Infection			
subjects affected / exposed	3 / 3032 (0.10%)	3 / 3031 (0.10%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary Tract Infection			
subjects affected / exposed	19 / 3032 (0.63%)	18 / 3031 (0.59%)	
occurrences causally related to treatment / all	0 / 22	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			

subjects affected / exposed	2 / 3032 (0.07%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral Corneal Ulcer			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral Infection			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound Infection			
subjects affected / exposed	2 / 3032 (0.07%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	2 / 3032 (0.07%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes Mellitus Inadequate Control			
subjects affected / exposed	18 / 3032 (0.59%)	8 / 3031 (0.26%)	
occurrences causally related to treatment / all	0 / 18	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic Ketoacidosis			
subjects affected / exposed	4 / 3032 (0.13%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Diabetic Metabolic Decompensation			

subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte Imbalance			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	7 / 3032 (0.23%)	4 / 3031 (0.13%)	
occurrences causally related to treatment / all	0 / 7	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemic Hyperosmolar Nonketotic Syndrome			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	4 / 3032 (0.13%)	5 / 3031 (0.16%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypocalcaemia			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	10 / 3032 (0.33%)	5 / 3031 (0.16%)	
occurrences causally related to treatment / all	3 / 11	4 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			

subjects affected / exposed	1 / 3032 (0.03%)	2 / 3031 (0.07%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	4 / 3032 (0.13%)	5 / 3031 (0.16%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemia			
subjects affected / exposed	1 / 3032 (0.03%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malnutrition			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic Acidosis			
subjects affected / exposed	0 / 3032 (0.00%)	1 / 3031 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obesity			
subjects affected / exposed	1 / 3032 (0.03%)	0 / 3031 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Placebo	Lixisenatide	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1270 / 3032 (41.89%)	1597 / 3031 (52.69%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	171 / 3032 (5.64%)	152 / 3031 (5.01%)	
occurrences (all)	211	197	
Cardiac disorders			

Angina Pectoris subjects affected / exposed occurrences (all)	200 / 3032 (6.60%) 267	177 / 3031 (5.84%) 217	
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	191 / 3032 (6.30%) 260	259 / 3031 (8.55%) 353	
Headache subjects affected / exposed occurrences (all)	148 / 3032 (4.88%) 205	187 / 3031 (6.17%) 247	
General disorders and administration site conditions Non-Cardiac Chest Pain subjects affected / exposed occurrences (all)	171 / 3032 (5.64%) 217	137 / 3031 (4.52%) 175	
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	227 / 3032 (7.49%) 313	237 / 3031 (7.82%) 308	
Nausea subjects affected / exposed occurrences (all)	179 / 3032 (5.90%) 259	659 / 3031 (21.74%) 1027	
Vomiting subjects affected / exposed occurrences (all)	82 / 3032 (2.70%) 100	257 / 3031 (8.48%) 378	
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	188 / 3032 (6.20%) 259	181 / 3031 (5.97%) 238	
Metabolism and nutrition disorders Hypoglycaemia subjects affected / exposed occurrences (all)	554 / 3032 (18.27%) 2137	609 / 3031 (20.09%) 2285	



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
02 December 2010	Following amendments were done: - Clarification regarding the inclusion/exclusion criteria taking into account the recommendation of the study committees (SC). - Addition of elevated cardiac injury biomarkers [troponin or creatin kinase (CK)-MB] as a requirement for the qualifying ACS event.- Clarification of the exclusion criteria related to cardiac procedures like coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI) and angiography. -Collection of blood samples for metabolic, inflammatory, and CV biomarkers for storage. -Optional pharmacogenetic testing, which was to be done only when the subject had signed a separate informed consent for pharmacogenetic sampling.- The end date of the study would be driven by accumulation of the primary adjudicated events and would happen when the study had accumulated 844 positively adjudicated primary CV outcome events. -Re-screening of subjects was allowed based upon both the investigator's medical judgment and the Sponsor's agreement. Nevertheless, one subject could be randomized only one time. -Patient-reported outcome (PRO) endpoints were added.-Definitions of components of the composite CV efficacy endpoints from the protocol were removed as these definitions were to be provided in the CAC Manual of operations. -The endpoint "hospitalization for coronary revascularization procedure" was replaced with "coronary revascularization procedure". - 15 mcg QD dose was allowed in case the 20 mcg QD dose was not tolerated. - The wording for the section "Monitoring of suspected pancreatitis was revised, based upon recommendations from pancreatitis experts.
27 July 2011	Following changes were made: -The objective was revised, based on the results of a recent animal study. The revised objective of the study was to demonstrate a beneficial cardiac outcome, "to demonstrate that lixisenatide can reduce CV morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for unstable angina) compared to placebo in subjects with type 2 diabetes melitus (T2DM) who recently experienced a spontaneous, biomarker-positive ACS event". - Inclusion and exclusion criteria were revised. -The procedure of pre-screening and signing of informed consent was modified, as candidate trial subjects could best be identified in the critical care facilities during their qualifying ACS admission. -The study period was modified, as the study recruitment was slower than previously predicted; an additional 10 months were added to the recruitment period. -Glycemia Committee was added as a study committee. - The rules for withdrawal from treatment were modified in order to ensure that subjects who developed severe renal dysfunction would permanently discontinue IMP.
06 February 2014	Following changes were made: -The maximal study duration was extended up to 58 months for each subject in order to allow all subjects to continue their participation after December 2013. - Addition of a new safety committee, Pancreatic Safety Assessment Committee (PSAC), since some cases of acute pancreatitis had been spontaneously reported with other marketed glucagon like peptide-1 (GLP-1) receptor agonists, and a possible association between GLP-1-based therapies and acute pancreatitis could not be fully excluded. The PSAC was to review all pancreatic events that had been reported on a specific pancreatic event AE form. The statistical analysis of these events was also added. -Change in the dose adaptation rules of the IMPs to allow for dosing at dinner time. - Change in reporting timeline from "within 1 working day" to "within 24 hours" for serious adverse events (SAEs) to comply with Ethics committee (EC) guidance document and same changes for AEs with prespecified monitoring with immediate notification were done. - Additional contacts with subjects were requested to collect CV endpoint events, since excessive accumulation of non-adjudicated events would directly affect the study timelines. - Categories of estimated glomerular filtration rate (eGFR) were modified following Food and Drug Administration (FDA) guidance.

---

Notes:

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported

---

### **Online references**

<http://www.ncbi.nlm.nih.gov/pubmed/25965710>

<http://www.ncbi.nlm.nih.gov/pubmed/26630143>